| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Maternal Mortality | 7 | 2019 | 461 | 1.57 | Why? |
| Obstetrics | 9 | 2020 | 859 | 1.48 | Why? |
| Pregnancy Complications | 12 | 2020 | 1388 | 1.44 | Why? |
| Cesarean Section | 9 | 2021 | 2089 | 1.24 | Why? |
| Gynecology | 5 | 2020 | 741 | 1.23 | Why? |
| Pregnancy Complications, Cardiovascular | 3 | 2020 | 231 | 0.91 | Why? |
| Postpartum Hemorrhage | 6 | 2020 | 144 | 0.88 | Why? |
| Fetal Development | 5 | 2018 | 173 | 0.78 | Why? |
| Pregnancy | 53 | 2021 | 23879 | 0.77 | Why? |
| Multiple Birth Offspring | 1 | 2018 | 1 | 0.76 | Why? |
| Labor Onset | 1 | 2018 | 4 | 0.76 | Why? |
| Venous Thromboembolism | 7 | 2019 | 4273 | 0.75 | Why? |
| Maternal Death | 2 | 2018 | 108 | 0.74 | Why? |
| Labor Presentation | 1 | 2018 | 13 | 0.74 | Why? |
| Parity | 2 | 2018 | 122 | 0.73 | Why? |
| Gestational Age | 9 | 2020 | 1488 | 0.72 | Why? |
| Dystocia | 1 | 2017 | 5 | 0.71 | Why? |
| Episiotomy | 1 | 2017 | 10 | 0.71 | Why? |
| Lacerations | 1 | 2017 | 35 | 0.67 | Why? |
| Shoulder | 1 | 2017 | 96 | 0.66 | Why? |
| Patient Safety | 6 | 2020 | 4885 | 0.57 | Why? |
| Anal Canal | 1 | 2017 | 367 | 0.53 | Why? |
| Delivery, Obstetric | 7 | 2021 | 1292 | 0.51 | Why? |
| Infant Mortality | 1 | 2015 | 268 | 0.51 | Why? |
| Heparin, Low-Molecular-Weight | 4 | 2018 | 1731 | 0.47 | Why? |
| Maternal Age | 5 | 2021 | 244 | 0.45 | Why? |
| Pregnancy Complications, Infectious | 10 | 2021 | 11559 | 0.42 | Why? |
| Carrier State | 3 | 2021 | 2100 | 0.40 | Why? |
| Patient Readmission | 5 | 2019 | 1543 | 0.39 | Why? |
| Labor, Induced | 2 | 2020 | 186 | 0.37 | Why? |
| Pre-Eclampsia | 4 | 2019 | 599 | 0.37 | Why? |
| Academic Medical Centers | 2 | 2020 | 3088 | 0.37 | Why? |
| Pregnancy, High-Risk | 2 | 2020 | 128 | 0.36 | Why? |
| Anthropometry | 3 | 2018 | 233 | 0.36 | Why? |
| Pregnancy Outcome | 7 | 2021 | 3803 | 0.35 | Why? |
| Chorion | 1 | 2007 | 4 | 0.35 | Why? |
| Ultrasonography, Prenatal | 5 | 2018 | 471 | 0.35 | Why? |
| New York City | 11 | 2021 | 7432 | 0.33 | Why? |
| Twins | 2 | 2018 | 115 | 0.32 | Why? |
| Diseases in Twins | 1 | 2007 | 86 | 0.31 | Why? |
| Hypertension, Pregnancy-Induced | 2 | 2019 | 208 | 0.31 | Why? |
| Puerperal Disorders | 2 | 2018 | 151 | 0.30 | Why? |
| Prenatal Care | 4 | 2020 | 1314 | 0.30 | Why? |
| Fetal Death | 2 | 2017 | 390 | 0.29 | Why? |
| Maternal Health Services | 3 | 2018 | 808 | 0.28 | Why? |
| Postpartum Period | 6 | 2019 | 936 | 0.26 | Why? |
| Antihypertensive Agents | 3 | 2020 | 1962 | 0.23 | Why? |
| Female | 57 | 2021 | 380317 | 0.23 | Why? |
| United States | 24 | 2021 | 46150 | 0.22 | Why? |
| Uterine Inertia | 1 | 2020 | 13 | 0.22 | Why? |
| Nicardipine | 1 | 2020 | 13 | 0.22 | Why? |
| Bronchial Spasm | 1 | 2020 | 13 | 0.21 | Why? |
| Obstetrics and Gynecology Department, Hospital | 2 | 2021 | 241 | 0.21 | Why? |
| Obstetric Labor, Premature | 2 | 2020 | 114 | 0.20 | Why? |
| Premature Birth | 6 | 2020 | 2151 | 0.20 | Why? |
| Pregnancy in Diabetics | 1 | 2020 | 56 | 0.20 | Why? |
| Uterine Hemorrhage | 1 | 2019 | 73 | 0.19 | Why? |
| Delivery Rooms | 1 | 2020 | 148 | 0.19 | Why? |
| Labor Stage, Second | 1 | 2018 | 12 | 0.19 | Why? |
| Trial of Labor | 1 | 2018 | 21 | 0.18 | Why? |
| Pregnancy Trimester, First | 3 | 2017 | 366 | 0.18 | Why? |
| Birth Certificates | 1 | 2018 | 34 | 0.18 | Why? |
| Oxytocics | 1 | 2018 | 47 | 0.18 | Why? |
| Vaginal Birth after Cesarean | 1 | 2018 | 16 | 0.18 | Why? |
| Hospitalization | 12 | 2021 | 54280 | 0.18 | Why? |
| Intermittent Pneumatic Compression Devices | 1 | 2018 | 40 | 0.18 | Why? |
| Tocolysis | 1 | 2017 | 2 | 0.18 | Why? |
| Ceftriaxone | 1 | 2020 | 365 | 0.18 | Why? |
| Inhibins | 1 | 2017 | 4 | 0.18 | Why? |
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 8 | 0.17 | Why? |
| Abruptio Placentae | 1 | 2017 | 59 | 0.17 | Why? |
| Pregnancy Trimester, Second | 2 | 2017 | 314 | 0.17 | Why? |
| Matrix Metalloproteinases | 1 | 2017 | 131 | 0.16 | Why? |
| New York | 3 | 2020 | 2488 | 0.16 | Why? |
| Organizational Culture | 1 | 2020 | 395 | 0.16 | Why? |
| alpha-Fetoproteins | 1 | 2017 | 72 | 0.16 | Why? |
| Patient Care Bundles | 1 | 2019 | 137 | 0.16 | Why? |
| Hysterectomy | 1 | 2018 | 171 | 0.16 | Why? |
| Risk Factors | 18 | 2021 | 71621 | 0.16 | Why? |
| Cervix Uteri | 1 | 2017 | 146 | 0.16 | Why? |
| Databases, Factual | 10 | 2019 | 6248 | 0.16 | Why? |
| American Heart Association | 1 | 2018 | 347 | 0.15 | Why? |
| Young Adult | 24 | 2021 | 93724 | 0.15 | Why? |
| Hospitals, Low-Volume | 1 | 2017 | 355 | 0.15 | Why? |
| Healthcare Disparities | 3 | 2018 | 3893 | 0.15 | Why? |
| Pregnancy, Twin | 1 | 2017 | 133 | 0.15 | Why? |
| Methadone | 1 | 2018 | 296 | 0.15 | Why? |
| Adult | 36 | 2021 | 244371 | 0.15 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.15 | Why? |
| Depression, Postpartum | 1 | 2019 | 282 | 0.14 | Why? |
| Anesthesia, General | 1 | 2020 | 470 | 0.14 | Why? |
| Humans | 59 | 2021 | 930598 | 0.14 | Why? |
| Linear Models | 5 | 2019 | 1914 | 0.14 | Why? |
| Women's Health | 1 | 2020 | 444 | 0.14 | Why? |
| Personnel Staffing and Scheduling | 2 | 2021 | 1578 | 0.14 | Why? |
| National Institute of Child Health and Human Development (U.S.) | 3 | 2018 | 24 | 0.14 | Why? |
| Perinatal Care | 1 | 2020 | 576 | 0.13 | Why? |
| Body Fluids | 1 | 2017 | 451 | 0.13 | Why? |
| Hospitals, High-Volume | 1 | 2017 | 688 | 0.13 | Why? |
| Intersectoral Collaboration | 1 | 2020 | 1065 | 0.12 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.12 | Why? |
| Anticoagulants | 4 | 2018 | 9563 | 0.12 | Why? |
| Quality Improvement | 4 | 2019 | 2435 | 0.12 | Why? |
| Buprenorphine | 1 | 2018 | 470 | 0.12 | Why? |
| Enzyme Inhibitors | 2 | 2020 | 1881 | 0.12 | Why? |
| Birth Weight | 3 | 2018 | 250 | 0.11 | Why? |
| Blood Transfusion | 2 | 2018 | 1399 | 0.11 | Why? |
| Prenatal Diagnosis | 2 | 2020 | 345 | 0.11 | Why? |
| Iodide Peroxidase | 1 | 2010 | 19 | 0.11 | Why? |
| Early Diagnosis | 1 | 2019 | 2443 | 0.10 | Why? |
| Cohort Studies | 9 | 2021 | 36005 | 0.10 | Why? |
| Continuity of Patient Care | 1 | 2020 | 1574 | 0.10 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.10 | Why? |
| Patient Care Team | 2 | 2021 | 3556 | 0.10 | Why? |
| Oxygen Inhalation Therapy | 2 | 2020 | 3629 | 0.10 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2018 | 994 | 0.10 | Why? |
| Practice Patterns, Physicians' | 2 | 2018 | 4927 | 0.10 | Why? |
| Evidence-Based Medicine | 2 | 2019 | 3228 | 0.09 | Why? |
| Delivery of Health Care, Integrated | 1 | 2021 | 1549 | 0.09 | Why? |
| Analgesics, Opioid | 1 | 2018 | 1070 | 0.09 | Why? |
| Azithromycin | 2 | 2020 | 3943 | 0.09 | Why? |
| Heparin | 2 | 2018 | 2600 | 0.09 | Why? |
| Retrospective Studies | 14 | 2021 | 105322 | 0.08 | Why? |
| Patient Care Management | 1 | 2019 | 1514 | 0.08 | Why? |
| Opioid-Related Disorders | 1 | 2019 | 1185 | 0.08 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2021 | 3388 | 0.08 | Why? |
| Adolescent | 15 | 2019 | 86841 | 0.08 | Why? |
| Mothers | 1 | 2017 | 1624 | 0.08 | Why? |
| Fever | 2 | 2021 | 7795 | 0.08 | Why? |
| Depressive Disorder | 1 | 2017 | 1236 | 0.08 | Why? |
| Health Services Needs and Demand | 1 | 2021 | 3419 | 0.08 | Why? |
| Quality of Health Care | 1 | 2017 | 1948 | 0.07 | Why? |
| Surgical Procedures, Operative | 1 | 2021 | 2662 | 0.07 | Why? |
| Medicaid | 2 | 2020 | 492 | 0.07 | Why? |
| Risk | 1 | 2017 | 5288 | 0.07 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.07 | Why? |
| Thrombocytopenia | 1 | 2018 | 2093 | 0.07 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.07 | Why? |
| Family Planning Services | 2 | 2017 | 236 | 0.07 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2021 | 5164 | 0.06 | Why? |
| Stress, Psychological | 2 | 2017 | 10231 | 0.06 | Why? |
| Infant, Newborn | 6 | 2021 | 23105 | 0.06 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.06 | Why? |
| Down Syndrome | 1 | 2007 | 397 | 0.06 | Why? |
| Communication | 1 | 2020 | 5206 | 0.06 | Why? |
| Odds Ratio | 3 | 2018 | 5861 | 0.06 | Why? |
| Postoperative Complications | 1 | 2021 | 5861 | 0.06 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.06 | Why? |
| Prospective Studies | 8 | 2020 | 43301 | 0.06 | Why? |
| Chorioamnionitis | 1 | 2021 | 50 | 0.06 | Why? |
| Consensus | 1 | 2016 | 6345 | 0.06 | Why? |
| Health Services Research | 2 | 2017 | 756 | 0.06 | Why? |
| Mass Screening | 2 | 2020 | 8005 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.05 | Why? |
| Treatment Outcome | 2 | 2019 | 51732 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2020 | 10083 | 0.05 | Why? |
| Workflow | 2 | 2021 | 2373 | 0.05 | Why? |
| Obesity | 2 | 2020 | 7388 | 0.05 | Why? |
| Fetal Monitoring | 1 | 2020 | 80 | 0.05 | Why? |
| Multi-Institutional Systems | 1 | 2020 | 97 | 0.05 | Why? |
| Telemedicine | 3 | 2020 | 25032 | 0.05 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.05 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.05 | Why? |
| Tachypnea | 1 | 2020 | 197 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.05 | Why? |
| Carboprost | 1 | 2018 | 2 | 0.05 | Why? |
| Asthma | 1 | 2018 | 4383 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.05 | Why? |
| Peripartum Period | 1 | 2019 | 89 | 0.05 | Why? |
| Labetalol | 1 | 2018 | 13 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2020 | 6166 | 0.05 | Why? |
| Autoantibodies | 1 | 2010 | 2094 | 0.05 | Why? |
| Facility Design and Construction | 1 | 2020 | 189 | 0.05 | Why? |
| Stockings, Compression | 1 | 2018 | 20 | 0.05 | Why? |
| Evaluation Studies as Topic | 1 | 2020 | 391 | 0.05 | Why? |
| New Jersey | 1 | 2020 | 528 | 0.05 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2021 | 265 | 0.05 | Why? |
| Needs Assessment | 2 | 2021 | 2352 | 0.05 | Why? |
| Transitional Care | 1 | 2020 | 135 | 0.05 | Why? |
| Humerus | 1 | 2018 | 19 | 0.05 | Why? |
| Fetal Weight | 1 | 2018 | 24 | 0.04 | Why? |
| Professional Practice Location | 1 | 2018 | 31 | 0.04 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.04 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.04 | Why? |
| Hospitals, Maternity | 1 | 2019 | 154 | 0.04 | Why? |
| Hirudins | 1 | 2018 | 75 | 0.04 | Why? |
| Estriol | 1 | 2017 | 5 | 0.04 | Why? |
| Oxytocin | 1 | 2018 | 76 | 0.04 | Why? |
| Cephalometry | 1 | 2017 | 41 | 0.04 | Why? |
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2017 | 27 | 0.04 | Why? |
| Pipecolic Acids | 1 | 2018 | 84 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Stroke | 2 | 2018 | 8839 | 0.04 | Why? |
| Reverse Transcription | 1 | 2021 | 673 | 0.04 | Why? |
| Longitudinal Studies | 3 | 2018 | 9893 | 0.04 | Why? |
| Genetic Counseling | 1 | 2020 | 229 | 0.04 | Why? |
| Contraindications, Drug | 1 | 2018 | 281 | 0.04 | Why? |
| Asymptomatic Diseases | 2 | 2020 | 3444 | 0.04 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.04 | Why? |
| Femur | 1 | 2018 | 100 | 0.04 | Why? |
| Labor, Obstetric | 1 | 2020 | 257 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2019 | 15421 | 0.04 | Why? |
| Obstetric Labor Complications | 1 | 2018 | 119 | 0.04 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.04 | Why? |
| Body Height | 1 | 2017 | 100 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.04 | Why? |
| Mental Disorders | 1 | 2019 | 6742 | 0.04 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.04 | Why? |
| Indians, North American | 1 | 2018 | 195 | 0.04 | Why? |
| Hospitals, Community | 1 | 2020 | 475 | 0.04 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.04 | Why? |
| Confidence Intervals | 1 | 2018 | 744 | 0.04 | Why? |
| Fluid Therapy | 1 | 2020 | 628 | 0.04 | Why? |
| Arginine | 1 | 2018 | 377 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| Models, Organizational | 1 | 2021 | 908 | 0.03 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.03 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.03 | Why? |
| Guideline Adherence | 2 | 2018 | 2309 | 0.03 | Why? |
| Morbidity | 1 | 2021 | 1426 | 0.03 | Why? |
| Asian Americans | 1 | 2018 | 387 | 0.03 | Why? |
| Body Mass Index | 2 | 2017 | 4306 | 0.03 | Why? |
| Perinatal Death | 1 | 2017 | 372 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Research Support as Topic | 1 | 2017 | 327 | 0.03 | Why? |
| Abdomen | 1 | 2017 | 424 | 0.03 | Why? |
| Cost-Benefit Analysis | 2 | 2018 | 2259 | 0.03 | Why? |
| Risk Assessment | 4 | 2018 | 25439 | 0.03 | Why? |
| African Americans | 2 | 2019 | 3363 | 0.03 | Why? |
| Risk Management | 1 | 2021 | 1044 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Developed Countries | 1 | 2017 | 500 | 0.03 | Why? |
| Quality Assurance, Health Care | 1 | 2018 | 596 | 0.03 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| Weight Gain | 1 | 2017 | 552 | 0.03 | Why? |
| Clinical Competence | 2 | 2017 | 3263 | 0.03 | Why? |
| Opiate Substitution Treatment | 1 | 2018 | 613 | 0.03 | Why? |
| Patient Discharge | 2 | 2019 | 5696 | 0.03 | Why? |
| Medicare | 1 | 2019 | 1048 | 0.03 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.03 | Why? |
| Hospitals, Urban | 1 | 2017 | 950 | 0.03 | Why? |
| Ireland | 1 | 2017 | 1456 | 0.03 | Why? |
| Health Status Disparities | 2 | 2020 | 4072 | 0.03 | Why? |
| Demography | 1 | 2018 | 1660 | 0.03 | Why? |
| Breast Feeding | 1 | 2021 | 1585 | 0.03 | Why? |
| Residence Characteristics | 1 | 2021 | 1927 | 0.03 | Why? |
| Fetal Membranes, Premature Rupture | 1 | 2010 | 122 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.02 | Why? |
| Sulfonamides | 1 | 2018 | 1294 | 0.02 | Why? |
| Health Priorities | 1 | 2017 | 959 | 0.02 | Why? |
| Karyotyping | 1 | 2007 | 52 | 0.02 | Why? |
| Qualitative Research | 1 | 2020 | 4337 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Electronic Health Records | 1 | 2020 | 3492 | 0.02 | Why? |
| Peptide Fragments | 1 | 2018 | 2075 | 0.02 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.02 | Why? |
| Minority Groups | 1 | 2017 | 1631 | 0.02 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.02 | Why? |
| Critical Pathways | 1 | 2017 | 1587 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.02 | Why? |
| Hypoxia | 1 | 2020 | 3626 | 0.02 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.02 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.02 | Why? |
| Quality-Adjusted Life Years | 1 | 2007 | 511 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.01 | Why? |
| False Positive Reactions | 1 | 2007 | 1338 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2020 | 4741 | 0.01 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Male | 4 | 2021 | 367725 | 0.01 | Why? |
| Registries | 1 | 2018 | 12327 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2021 | 23402 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2007 | 7330 | 0.01 | Why? |
| Aged | 1 | 2021 | 215776 | 0.00 | Why? |